NO924502D0 - Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser - Google Patents

Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Info

Publication number
NO924502D0
NO924502D0 NO1992924502A NO924502A NO924502D0 NO 924502 D0 NO924502 D0 NO 924502D0 NO 1992924502 A NO1992924502 A NO 1992924502A NO 924502 A NO924502 A NO 924502A NO 924502 D0 NO924502 D0 NO 924502D0
Authority
NO
Norway
Prior art keywords
piperazine
carboxamids
treatment
substance abuse
new use
Prior art date
Application number
NO1992924502A
Other languages
English (en)
Other versions
NO301311B1 (no
NO924502L (no
Inventor
Anders Bjoerk
Erik Christensson
Original Assignee
Kabi Pharmacia Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kabi Pharmacia Ab filed Critical Kabi Pharmacia Ab
Publication of NO924502D0 publication Critical patent/NO924502D0/no
Publication of NO924502L publication Critical patent/NO924502L/no
Publication of NO301311B1 publication Critical patent/NO301311B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Addiction (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Psychiatry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicinal Preparation (AREA)
NO924502A 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser NO301311B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9100860A SE9100860D0 (sv) 1991-03-22 1991-03-22 New use
PCT/SE1992/000182 WO1992016211A1 (en) 1991-03-22 1992-03-23 New use of diphenylbutyl-piperazinecarboxamides in the treatment of substance disorders

Publications (3)

Publication Number Publication Date
NO924502D0 true NO924502D0 (no) 1992-11-23
NO924502L NO924502L (no) 1992-11-23
NO301311B1 NO301311B1 (no) 1997-10-13

Family

ID=20382242

Family Applications (1)

Application Number Title Priority Date Filing Date
NO924502A NO301311B1 (no) 1991-03-22 1992-11-23 Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser

Country Status (24)

Country Link
US (2) US5434156A (no)
EP (1) EP0538422B1 (no)
JP (1) JP3221611B2 (no)
KR (1) KR100196674B1 (no)
AT (1) ATE199057T1 (no)
AU (1) AU653797B2 (no)
BG (1) BG61829B1 (no)
BR (1) BR9204969A (no)
CA (1) CA2083505C (no)
CZ (1) CZ282222B6 (no)
DE (1) DE69231680T2 (no)
DK (1) DK0538422T3 (no)
EE (1) EE02973B1 (no)
ES (1) ES2154261T3 (no)
GR (1) GR3035805T3 (no)
HU (2) HU217833B (no)
IE (1) IE920920A1 (no)
NO (1) NO301311B1 (no)
PT (1) PT100279B (no)
RO (1) RO109702B1 (no)
RU (1) RU2095062C1 (no)
SE (1) SE9100860D0 (no)
SK (1) SK279237B6 (no)
WO (1) WO1992016211A1 (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use
SE9201239D0 (sv) * 1992-04-21 1992-04-21 Kabi Pharmacia Ab Agents for treating substance abuse disorders
JP3571114B2 (ja) * 1995-07-11 2004-09-29 ポーラ化成工業株式会社 麻薬拮抗剤
US6265393B1 (en) 1998-08-07 2001-07-24 Heinrichs William Leroy Prevention of endometriosis signs or symptons
US6090780A (en) * 1999-04-07 2000-07-18 Chandon Prasad Histidyl-proline diketopiperazine and method of use
USRE39921E1 (en) 1999-10-07 2007-11-13 Smithkline Beecham Corporation Chemical compounds
GB9923748D0 (en) 1999-10-07 1999-12-08 Glaxo Group Ltd Chemical compounds
GB0025354D0 (en) 2000-10-17 2000-11-29 Glaxo Group Ltd Chemical compounds
US20050192271A1 (en) * 2003-07-15 2005-09-01 Hythiam, Inc. Use of selective chloride channel modulators to treat alcohol and/or stimulant substance abuse
CA2433833C (en) * 2001-01-17 2009-06-02 Juan Jose Legarda Ibanez Use of flumazenil in developing a drug for the treatment of alcohol dependence
US7183410B2 (en) * 2001-08-02 2007-02-27 Bidachem S.P.A. Stable polymorph of flibanserin
US20030060475A1 (en) * 2001-08-10 2003-03-27 Boehringer Ingelheim Pharma Kg Method of using flibanserin for neuroprotection
US10675280B2 (en) 2001-10-20 2020-06-09 Sprout Pharmaceuticals, Inc. Treating sexual desire disorders with flibanserin
UA78974C2 (en) 2001-10-20 2007-05-10 Boehringer Ingelheim Pharma Use of flibanserin for treating disorders of sexual desire
GB0203022D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
EP1472222A1 (en) 2002-02-08 2004-11-03 Glaxo Group Limited Piperidylcarboxamide derivatives and their use in the treatment of tachykinim-mediated diseases
GB0203020D0 (en) 2002-02-08 2002-03-27 Glaxo Group Ltd Chemical compounds
US20050239798A1 (en) * 2004-04-22 2005-10-27 Boehringer Ingelheim Pharmaceuticals, Inc. Method for the treatment of premenstrual and other female sexual disorders
MXPA06012059A (es) * 2004-04-22 2007-01-25 Boehringer Ingelheim Int Nuevas composiciones farmaceuticas para el tratamiento de los trastornos sexuales ii.
US20060025420A1 (en) * 2004-07-30 2006-02-02 Boehringer Ingelheimn International GmbH Pharmaceutical compositions for the treatment of female sexual disorders
JP2008511569A (ja) * 2004-09-03 2008-04-17 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 注意欠如活動過多障害の治療方法
WO2006096439A2 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of schizophrenia and related diseases
CA2599721A1 (en) * 2005-03-04 2006-09-14 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of depression
EP1858515A2 (en) * 2005-03-04 2007-11-28 Boehringer Ingelheim International Gmbh Pharmaceutical compositions for the treatment and/or prevention of anxiety disorders
CA2608249A1 (en) * 2005-05-06 2006-11-16 Boehringer Ingelheim International Gmbh Method for the treatment of drug abuse with flibanserin
CA2608363A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of drug-induced sexual dysfunction
CA2608713A1 (en) * 2005-05-19 2006-11-23 Boehringer Ingelheim International Gmbh Method for the treatment of sexual dysfunctions due to medical conditions
JP2009503020A (ja) 2005-08-03 2009-01-29 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 肥満症の治療におけるフリバンセリンの使用
US20070123540A1 (en) * 2005-10-29 2007-05-31 Angelo Ceci Sexual desire enhancing medicaments comprising benzimidazolone derivatives
WO2007048803A1 (en) * 2005-10-29 2007-05-03 Boehringer Ingelheim International Gmbh Benzimidazolone derivatives for the treatment of premenstrual and other female sexual disorders
US20070105869A1 (en) * 2005-11-08 2007-05-10 Stephane Pollentier Use of flibanserin for the treatment of pre-menopausal sexual desire disorders
WO2007128802A2 (en) * 2006-05-09 2007-11-15 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of post-menopausal sexual desire disorders
JP2009541443A (ja) 2006-06-30 2009-11-26 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 尿失禁及び関連疾患の治療のためのフリバンセリン
CA2657043A1 (en) * 2006-07-14 2008-01-17 Boehringer Ingelheim International Gmbh Use of flibanserin for the treatment of sexual disorders in females
EA200900264A1 (ru) 2006-08-14 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Композиции флибансерина и способ их приготовления
CL2007002214A1 (es) * 2006-08-14 2008-03-07 Boehringer Ingelheim Int Composicion farmaceutica en la forma de comprimido, donde al menos la longitud del comprimido en el estado anterior de la aplicacion es al menos 7/12 del diametro pilorico del paciente y despues de ingerirlo en estado alimentado, la longitud del comp
EA200900270A1 (ru) * 2006-08-25 2009-08-28 Бёрингер Ингельхайм Интернациональ Гмбх Системы регулируемого высвобождения и способ их приготовления
PE20091188A1 (es) 2007-09-12 2009-08-31 Boehringer Ingelheim Int Compuesto 1-[2-(4-(3-trifluorometil-fenil)piperazin-1-il)etil]-2,3-dihidro-1h-benzimidazol-2-ona (flibanserina), sus sales de adicion y composiciones farmaceuticas que los contienen

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO154582C (no) * 1978-10-20 1986-11-05 Ferrosan Ab Analogifremgangsmaate for fremstilling av terapeutisk aktive difenyl-dibutylpiperazinkarboksamider.
SE9100860D0 (sv) * 1991-03-22 1991-03-22 Kabi Pharmacia Ab New use

Also Published As

Publication number Publication date
BG61829B1 (bg) 1998-07-31
EE02973B1 (et) 1997-04-15
CZ344992A3 (en) 1994-02-16
HUT64696A (en) 1994-02-28
SK344992A3 (en) 1995-11-08
IE920920A1 (en) 1992-09-23
HU217833B (hu) 2000-04-28
KR930700108A (ko) 1993-03-13
SE9100860D0 (sv) 1991-03-22
BR9204969A (pt) 1993-07-27
HU9203632D0 (en) 1993-03-29
KR100196674B1 (ko) 1999-06-15
US5618817A (en) 1997-04-08
GR3035805T3 (en) 2001-07-31
PT100279A (pt) 1993-07-30
US5434156A (en) 1995-07-18
WO1992016211A1 (en) 1992-10-01
SK279237B6 (sk) 1998-08-05
JP3221611B2 (ja) 2001-10-22
AU653797B2 (en) 1994-10-13
DE69231680D1 (de) 2001-03-15
CZ282222B6 (cs) 1997-06-11
ATE199057T1 (de) 2001-02-15
CA2083505C (en) 2003-06-10
AU1428092A (en) 1992-10-21
DE69231680T2 (de) 2001-06-07
CA2083505A1 (en) 1992-09-23
JPH05507731A (ja) 1993-11-04
ES2154261T3 (es) 2001-04-01
NO301311B1 (no) 1997-10-13
NO924502L (no) 1992-11-23
DK0538422T3 (da) 2001-05-07
EP0538422A1 (en) 1993-04-28
EP0538422B1 (en) 2001-02-07
BG97108A (bg) 1994-03-24
RO109702B1 (ro) 1995-05-30
PT100279B (pt) 1999-06-30
RU2095062C1 (ru) 1997-11-10

Similar Documents

Publication Publication Date Title
NO924502L (no) Ny anvendelse av difenylbutyl-piperazinkarboksamider ved behandling av stoffmisbruklidelser
NO931267L (no) Fremgangsmaate for behandling eller forebyggelse av type 1diabetes ved oral administrering av insulin
UA26213C2 (uk) Засіб для профілактики та лікуваhhя остеопорозу та фармацевтичhа композиція hа їх осhові
FI964332A (fi) Eräiden metaanibisfosfonihappojohdannaisten käyttö proteesin löystymisen ja proteesin vaelluksen estämiseen
ATE74271T1 (de) Ketonderivate als arzneimittel zur behandlung oder vorbeugung des entzugssyndromes.
NO20010627L (no) Anvendelse av Gingko Biloba ekstrakter for fremstilling av et medikament for behandling av amyotrofisk lateral sclerose
KR100321319B1 (ko) 물질남용장애를치료하는방법및제약학적조성물
NO934832L (no) Farmasöytisk sammensetning for forhindring eller behandling av arterioscherose
SE9303612D0 (sv) New use
KR880009656A (ko) 국소 치근막 질환의 치료 또는 예방법
KR940011006A (ko) 황금추출물을 유효성분으로 하는 치주질환예방 및 치료제 조성물
RU94044455A (ru) Средство для усиления функции макрофага и лечения человека с ослабленным иммунитетом
KR940003550A (ko) 노인성 치매 예방 및 치료방법
KR880012231A (ko) 스테로이드의 용도